SciClone Plummets After Cutting Guidance, Says It's Not Talking To Any Acquirers

By: via Benzinga
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) revealed an update on its tactical review process, which was disclosed in February. ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.